BioMarin Pharmaceutical Inc. (BMRN) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
BMRN's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
BMRN Revenue Analysis (2014–2025)
As of March 1, 2026, BioMarin Pharmaceutical Inc. (BMRN) generated trailing twelve-month (TTM) revenue of $3.22 billion, reflecting strong growth of +17.0% year-over-year. The most recent quarter (Q4 2025) recorded $874.6 million in revenue, up 12.7% sequentially.
Looking at the longer-term picture, BMRN's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $2.85 billion in 2024.
Revenue diversification analysis shows BMRN's business is primarily driven by Product (98%), and Royalty And Other (2%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AGIO (+36.3% YoY), VRTX (+10.4% YoY), and ASND (+97.4% YoY), BMRN has underperformed the peer group in terms of revenue growth. Compare BMRN vs AGIO →
Peer Comparison
Compare BMRN's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BMRNCurrent | $3.2B | +17.0% | - | - | |
| AGIO | $54M | +36.3% | - | -873.9% | |
| VRTX | $12.0B | +10.4% | +14.1% | 39.1% | |
| ASND | $692M | +97.4% | +150.9% | -18.9% | |
| BBIO | $502M | +126.3% | +127.4% | -113.3% | |
| PTCT | $1.7B | +97.5% | +35.4% | 50.1% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $0 | - | $0 | - |
| 2024 | $2.85B | +18.0% | $2.27B | 79.7% | $484.2M | 17.0% |
| 2023 | $2.42B | +15.4% | $1.89B | 78.0% | $185.8M | 7.7% |
| 2022 | $2.10B | +13.5% | $1.59B | 76.0% | $161.0M | 7.7% |
| 2021 | $1.85B | -0.8% | $1.38B | 74.5% | $-82,341,000 | -4.5% |
| 2020 | $1.86B | +9.2% | $1.34B | 71.8% | $-43,440,000 | -2.3% |
| 2019 | $1.70B | +14.3% | $1.34B | 78.9% | $-100,457,000 | -5.9% |
| 2018 | $1.49B | +13.5% | $1.18B | 78.9% | $-123,524,000 | -8.3% |
| 2017 | $1.31B | +17.6% | $1.07B | 81.6% | $-14,700,000 | -1.1% |
| 2016 | $1.12B | +25.5% | $907.2M | 81.2% | $-803,429,000 | -71.9% |
See BMRN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BMRN Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare BMRN vs AGIO
See how BMRN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is BMRN's revenue growth accelerating or slowing?
BMRN revenue is accelerating at +17.0% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $3.2B. Growth momentum has increased versus prior periods.
What is BMRN's long-term revenue growth rate?
BioMarin Pharmaceutical Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +17.0% is above this long-term average.
How is BMRN's revenue distributed by segment?
BMRN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.